FDMT · 4D Molecular Therapeutics, Inc. · Executive Compensation
$12.93
+0.97 (+8.11%)
At close · Oct 28
Return incl. dividend (before tax)
Market Cap
$863.27M
Shares
72.18M
Volume · Oct 28
1.19M
Avg daily vol (3M)
996.07K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| David Kirn | President and Chief Executive Officer | $2,051,343 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| David Kirn | Chief Executive Officer | $1,009,004 |
| Uneek Mehra | Chief Financial and Business Officer | $823,899 |
| Fariborz Kamal | Chief Operating Officer & President | $734,607 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| David Kirn | Chief Executive Officer | $10,286,808 |
| Fariborz Kamal | Chief Operating Officer & President | $4,544,260 |
| Robert Kim | Chief Medical Officer | $3,964,950 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David Kirn | Chief Executive Officer | $3,287,970 |
| Fariborz Kamal | Chief Operating Officer & President | $2,386,301 |
| August J. Moretti | Chief Financial Officer | $2,173,940 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| David Kirn | Chief Executive Officer | $5,200,825 |
| August J. Moretti | Chief Financial Officer | $2,635,785 |
| Theresa Janke | Chief of Staff | $2,572,695 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Robert Fishman | Chief Medical Officer | $3,339,803 |
| David Kirn | Chief Executive Officer | $701,533 |
| August J. Moretti | Chief Financial Officer | $632,762 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| August J. Moretti | Chief Financial Officer | $2,137,710 |
| David Kirn | Chief Executive Officer | $554,300 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kristian Humer | Principal Accounting Officer | Appointed | 2026-03-30 |
| Glenn Sblendorio | Class I director | Appointed | 2026-01-07 |
| David Kirn, M.D. | President and Chief Executive Officer | Appointed | 2026-01-07 |
| Fariborz Kamal, Ph.D. | President and Chief Operating Officer | Resigned | 2026-01-07 |
| Kristian Humer | Chief Financial Officer and Principal Financial Officer | Appointed | 2025-11-17 |
| Ashoo Gupta | Principal Financial Officer and Principal Accounting Officer | Appointed | 2025-10-02 |
| Uneek Mehra | Chief Financial and Business Officer | Resigned | 2025-07-02 |
| Noriyuki Kasahara, M.D., Ph.D. | member and the Chair of the Science and Technology Committee of the Board | Resigned | 2024-01-04 |
| Uneek Mehra | Chief Financial and Business Officer, Principal Financial Officer, Principal Accounting Officer, and Assistant Secretary | Appointed | 2023-09-13 |
| August J. Moretti | Chief Financial Officer and Assistant Secretary | Retired | 2023-09-13 |
| Noriyuki Kasahara, M.D., Ph.D. | Class I director | Appointed | 2022-09-27 |
Leadership
- David Kirn CEO, Board Member
- David Kirn, M.D. CEO
- Ashoo Gupta CFO
- Kristian Humer CFO, Chief Accounting Officer
- Uneek Mehra CFO, Chief Accounting Officer
- Fred Kamal COO
- Charles Theuer Board Member
- Glenn Sblendorio Board Member
- Jacob Chacko Board Member
- John F. Milligan Board Member
- Nancy Miller-Rich Board Member
- Noriyuki Kasahara, M.D., Ph.D. Board Member
- Shawn Cline Tomasello Board Member
- Susannah Gray Board Member
Key facts
CIK
1650648
CUSIP
35104E100
13F (30d)
20 filings
20 filers
Visit website
Investor relations